[go: up one dir, main page]

UY24006A1 - Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol. - Google Patents

Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.

Info

Publication number
UY24006A1
UY24006A1 UY24006A UY24006A UY24006A1 UY 24006 A1 UY24006 A1 UY 24006A1 UY 24006 A UY24006 A UY 24006A UY 24006 A UY24006 A UY 24006A UY 24006 A1 UY24006 A1 UY 24006A1
Authority
UY
Uruguay
Prior art keywords
purin
oxo
amino
derived
metoxil
Prior art date
Application number
UY24006A
Other languages
English (en)
Inventor
Nestor John
Womble Scott
Maag Hans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY24006A1 publication Critical patent/UY24006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describe el éster de L-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi-1,3-propandiol y sus sales farmacéuticamente aceptables que son valiosos como agentes antivirales con absorción mejorada
UY24006A 1994-07-28 1995-07-27 Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol. UY24006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28

Publications (1)

Publication Number Publication Date
UY24006A1 true UY24006A1 (es) 2001-07-31

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24006A UY24006A1 (es) 1994-07-28 1995-07-27 Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.

Country Status (32)

Country Link
EP (1) EP0694547B1 (es)
JP (1) JP3090305B2 (es)
KR (1) KR100358626B1 (es)
CN (1) CN1045089C (es)
AT (1) ATE179173T1 (es)
AU (1) AU697107B2 (es)
BR (1) BR9503468A (es)
CA (1) CA2154721C (es)
CO (1) CO4410181A1 (es)
CY (2) CY2180B1 (es)
CZ (1) CZ290511B6 (es)
DE (3) DE694547T1 (es)
DK (1) DK0694547T3 (es)
ES (1) ES2083348T3 (es)
FI (1) FI112080B (es)
GR (2) GR960300021T1 (es)
HU (1) HU216867B (es)
IL (1) IL114735A (es)
LU (1) LU91136I2 (es)
MA (1) MA23631A1 (es)
MY (1) MY114393A (es)
NL (1) NL300071I2 (es)
NO (2) NO312899B1 (es)
NZ (1) NZ272652A (es)
PE (1) PE32296A1 (es)
PL (1) PL180609B1 (es)
RU (1) RU2133749C1 (es)
SA (1) SA95160158B1 (es)
TR (1) TR199500895A2 (es)
TW (1) TW434242B (es)
UY (1) UY24006A1 (es)
ZA (1) ZA956228B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
WO1997027198A1 (en) * 1996-01-26 1997-07-31 F.Hoffmann-La Roche Ag Process for preparing purine derivatives
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
DE69809205T2 (de) * 1997-02-10 2003-05-28 Medivir Ab, Huddinge Verfahren zur herstellung von azyklischen nukleosiden
DE69800753D1 (de) * 1997-08-15 2001-06-07 Medivir Ab Huddinge Analoge nukleoside, wie antivirale einschliesslich inhibitoren der retroviralen reverstranskriptase und der dna polymerase des hepatitis b virus
AU1711599A (en) * 1997-12-19 1999-07-12 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
JP2000256359A (ja) * 1999-03-11 2000-09-19 Japan Science & Technology Corp 面性キラリティーを有する分子群の高選択的不斉変換法
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
DE60313769T2 (de) * 2002-04-23 2008-03-06 Aventis Pharmaceuticals Inc. 3-(pyridinyl-amino)-1h-indol-2-carbonsäure-verbindungen als inhibitoren der interleukin-4 genexpression
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CA2537132A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
BRPI0818286A2 (pt) 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
CN103562207B (zh) * 2011-05-31 2016-08-17 法尔玛赞公司 用于制备缬更昔洛韦的2-氨基-9-((2-苯基-1，3-二噁烷-5-基氧基)甲基)-1h-嘌呤-6(9h)-酮化合物的制备方法
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
IE58569B1 (en) * 1984-12-12 1993-10-06 Syntex Inc Alkoxy methyl ether and alkoxy methyl ester derivatives
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
AU618436B2 (en) * 1988-12-19 1991-12-19 Wellcome Foundation Limited, The Antiviral cytosine and guanine derivatives

Also Published As

Publication number Publication date
CN1045089C (zh) 1999-09-15
GR960300021T1 (en) 1996-04-30
NO2003001I2 (no) 2007-06-11
NO312899B1 (no) 2002-07-15
RU2133749C1 (ru) 1999-07-27
CZ193995A3 (en) 1996-02-14
JPH0841061A (ja) 1996-02-13
NL300071I1 (nl) 2002-02-01
NO952977D0 (no) 1995-07-27
DE69509173T2 (de) 1999-10-21
IL114735A0 (en) 1995-11-27
DE10299032I1 (de) 2003-01-23
HU9502238D0 (en) 1995-09-28
DK0694547T3 (da) 2000-01-03
SA95160158B1 (ar) 2006-05-20
ZA956228B (en) 1996-02-22
ES2083348T1 (es) 1996-04-16
HK1012339A1 (en) 1999-07-30
TW434242B (en) 2001-05-16
LU91136I2 (fr) 2005-07-06
FI953592L (fi) 1996-01-29
NZ272652A (en) 1996-12-20
CY2004003I1 (el) 2009-11-04
TR199500895A2 (tr) 1996-06-21
EP0694547B1 (en) 1999-04-21
ATE179173T1 (de) 1999-05-15
EP0694547A3 (en) 1996-06-05
MY114393A (en) 2002-10-31
CY2180B1 (en) 2002-08-23
CA2154721A1 (en) 1996-01-29
FI953592A0 (fi) 1995-07-27
GR3030678T3 (en) 1999-11-30
HUT73246A (en) 1996-07-29
NO952977L (no) 1996-01-29
RU95113148A (ru) 1997-06-27
FI112080B (fi) 2003-10-31
DE10299032I2 (de) 2006-06-14
PL180609B1 (pl) 2001-03-30
IL114735A (en) 1998-06-15
AU697107B2 (en) 1998-09-24
CZ290511B6 (cs) 2002-08-14
BR9503468A (pt) 1996-02-27
ES2083348T3 (es) 1999-08-01
NL300071I2 (nl) 2002-03-01
EP0694547A2 (en) 1996-01-31
HU216867B (hu) 1999-09-28
MA23631A1 (fr) 1996-04-01
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
PE32296A1 (es) 1996-08-07
CY2004003I2 (el) 2009-11-04
CN1122804A (zh) 1996-05-22
KR100358626B1 (ko) 2003-01-14
PL309812A1 (en) 1996-02-05
CA2154721C (en) 2001-01-02
JP3090305B2 (ja) 2000-09-18
KR960004345A (ko) 1996-02-23
CO4410181A1 (es) 1997-01-09
AU2719595A (en) 1996-02-08

Similar Documents

Publication Publication Date Title
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
MX9305277A (es) Monohidrato de 5-(2-4(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-dihidro-2h-indol-2-1-clorhidrato.
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
MX9401195A (es) Oligomeros de esteres tapados en los extremos poli-etoxi/propoxisulfonados adecuados como agentes liberadores de sucio en composicionesdetergentes.
EA199800667A1 (ru) Новые фенантридины
ES2105525T3 (es) 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
SV1996000033A (es) Isotiazolonas
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
ES2149690B1 (es) Cinta adhesiva a base de una tela no tejida mali.
ES2134178T1 (es) Tensoactivos de acido n-acil etilendiamintriacetico como tensoactivos compatibles con enzimas, estabilizadores y activadores.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2123873T3 (es) Pirrolocarbazol.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
GT199500039AA (es) Compuestos ariltios
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
ECSP951495A (es) Derivado de 2-(2-amino-1,6- dihidro-6-oxo- purin-9-il) metoxi-1,3- propan-diol
GT199800183A (es) Imidazotriazinonas sustituidas por 2-fenilo.
HN1998000197A (es) Compuestos de indol 2,3 sustituidas como agentes antiinflamatorios y analgesiscos.
ECSP961738A (es) Tetralinas
ECSP992888A (es) Pirroles sustituidos
SU1432991A1 (ru) 4-Метил-5-(4-метилфениламино)-1,2,3-триазол, обладающий противовоспалительной активностью
IT8023363V0 (it) Dispositivo di alimentazione per macchine utensili, nonche' macchina utensili munita del dispositivo.
IT232860Y1 (it) macchina per l'applicazione di collante su calzature.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20150727